Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies

Background Everolimus is an oral mTOR-inhibitor. Preclinical data show synergistic effects of mTOR inhibition in combination with 5-fluorouracil-based anticancer therapy. The combination of everolimus with capecitabine seems therefore an attractive new, orally available, treatment regimen. Patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Deenen, Maarten J., Klümpen, Heinz-Josef, Richel, Dick J., Sparidans, Rolf W., Weterman, Mariette J., Beijnen, Jos H., Schellens, Jan H. M., Wilmink, Johanna W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388253/
https://www.ncbi.nlm.nih.gov/pubmed/21809026
http://dx.doi.org/10.1007/s10637-011-9723-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3388253/
https://www.ncbi.nlm.nih.gov/pubmed/21809026
http://dx.doi.org/10.1007/s10637-011-9723-4

Ejemplares similares